HomeEXECUTIVESNevro Announces Director Appointment- Sri Kosaraju

Nevro Announces Director Appointment- Sri Kosaraju

Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced that Sri Kosaraju has been appointed as a member of the Board of Directors (the “Board”), effective August 31, 2021.

“We are delighted to have Sri join our Board of Directors,” said D. Keith Grossman, Chairman, President and CEO of Nevro. “Sri’s significant experience in leading high-growth life science and medical technology companies as well as his deep background in the healthcare industry will make him a valuable addition to our board. We look forward to Sri’s contributions to our Board of Directors and the continuing success of Nevro.”

“I’m excited to be joining Nevro’s Board,” said Mr. Kosaraju. “I have high respect for Keith and his leadership. Furthermore, I look forward to working with this world-class Board to support the Nevro team as it pursues impactful products for patients and continues to develop attractive long-term growth opportunities for its stakeholders.”

Mr. Kosaraju currently serves as the Chief Executive Officer and President of Inscripta, Inc., the digital genome engineering company, a position he has held since October 2020. Prior to joining Inscripta, Mr. Kosaraju was President of Penumbra, Inc., which he joined as CFO in May 2015. Earlier, Mr. Kosaraju spent 16 years at J.P. Morgan, where he was most recently Head of Healthcare Equity Capital Markets and Co-Head of Technology Equity Capital Markets. While at J.P. Morgan, he worked closely with and advised many emerging, high-growth life science and tech companies. In addition to serving on the Board of Directors for Inscripta, Mr. Kosaraju also currently serves on the Board of Directors and is the Chair of the Audit Committee of 10x Genomics, Inc. and is on the Board of the non-profit Testing for America.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.

By using this website you agree to accept Medical Device News Magazine Privacy Policy